The roles and clinical applications of mesenchymal stem cells and their exosomes in hematologic diseases Authors: Mengxue Deng, Xiaoying Zhang, Yicheng Zhang Published: 2025 ABSTRACT AbstractMesenchymal stem cells (MSCs) are multipotent stem cells with critical functions, including immunomodulation, multidirectional differentiation, anti-inflammatory activity, tissue repair, and regeneration. Recent studies demonstrate that MSCs can enhance hematopoietic stem cell engraftment, mitigate graft-versus-host disease (GVHD), address transplant-related complications, and treat conditions such as immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). These therapeutic effects are largely attributable to the immunomodulatory and anti-inflammatory properties of MSCs. However, in hematologic malignancies, MSCs can exert both pro-tumor and anti-tumor influences. Exosomes, which are extracellular vesicles derived from MSCs (MSC-EVs), not only replicate many MSC functions but also exhibit greater chemical stability and lower immunogenicity. These characteristics make MSC-EVs particularly significant in the context of hematopoietic stem cell transplantation (HSCT). This review provides a detailed overview of the roles and clinical applications of MSCs in hematologic diseases, the properties of MSC-EVs, and their emerging significance in HSCT.Keywords: Mesenchymal stem cells, Exosomes, Hematologic diseases, Hematopoietic stem cell transplantation, Graft-versus-host disease, Immunomodulation Introduction Hematologic diseases, encompassing both malignant and non-malignant disorders, pose significant challenges in clinical practice. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) serves as a cornerstone curative therapy for many of these conditions [1]. However, its efficacy is frequently limited by life-threatening complications, including graft failure, poor graft function (PGF), and graft-versus-host disease (GVHD [2]). Furthermore, managing refractory autoimmune cytopenias, such as immune thrombocytopenia (ITP [3]) and severe aplastic anemia (SAA [4]), often requires therapeutic strategies that go beyond conventional immunosuppression. Therefore, developing new approaches to improve hematopoietic reconstitution, modulate immune responses, and repair the bone marrow microenvironment is crucial in hematology. MSCs have emerged as promising cellular therapeutics due to their unique biological properties [5, 6]. These cells can be isolated from various sources, including bone marrow [7], umbilical cord [8], and adipose tissue [8]. MSCs possess the capacity for tri-lineage differentiation and exhibit potent immunomodulatory and trophic functions. Their mechanisms of action are multifaceted, involving direct cell-cell contact [9], the secretion of diverse soluble factors (such as PGE2, TGF-β, and IDO) [10], and metabolic reprogramming of the local microenvironment [11]. Furthermore, growing evidence indicates that extracellular vesicles (EVs) released by MSCs act as key mediators of these paracrine effects, significantly contributing to tissue repair and immune regulation. These properties enable MSCs to suppress detrimental immune responses, support hematopoietic recovery, and promote tissue regeneration. In the context of HSCT, preclinical and clinical studies demonstrate that MSCs can significantly enhance HSC engraftment by secreting supportive factors and repairing the damaged bone marrow niche [12–14]. Notably, their potent immunomodulatory capacity has been utilized to prevent and treat acute and chronic GVHD by rebalancing T-cell subsets, polarizing macrophages toward an anti-inflammatory M2 phenotype, and regulating aberrant B-cell responses [15, 16]. Beyond GVHD, MSCs infusions have shown promise in mitigating other transplant-related complications, including hemorrhagic cystitis [17]. However, the role of MSCs in hematologic malignancies is complex and represents a “double-edged sword.” While some studies demonstrate their anti-tumor effects by inducing cell cycle arrest and apoptosis in malignant cells [18], others report pro-tumorigenic activities, such as supporting cancer stemness and angiogenesis [19]. This duality highlights the necessity for careful selection of MSCs sources and for developing strategies to enhance their safety and efficacy, including the use of genetic engineering. Recently, MSC-EVs particularly exosomes, have garnered significant interest. These nanoscale vesicles carry the therapeutic cargo of their parent MSCs, including proteins, lipids, and nucleic acids, while offering distinct advantages such as lower immunogenicity, an improved safety profile, and the ability to cross biological barriers [20]. In preclinical models of GVHD and other inflammatory conditions, MSC-EVs have demonstrated efficacy comparable to that of whole MSCs, establishing them as a promising cell-free alternative therapy [21, 22]. This review comprehensively summarizes the current understanding of the biological functions of MSCs and their exosomes, explores their complex roles within the bone marrow microenvironment, and critically evaluates their expanding clinical applications across a spectrum of hematologic diseases, with a particular focus on their impact on HSCT outcomes. We also discuss prevailing challenges and future directions, including the engineering of MSCs and MSC-EVs to maximize therapeutic benefits while minimizing potential risks. Characteristics and functions of MSCs MSCs MSCs are a heterogeneous population of stromal cells characterized by a fibroblast-like morphology and multilineage differentiation potential. As adult stem cells, they are recognized for their robust self-renewal capacity and ability to differentiate into multiple cell lineages. Their broad tissue distribution and accessibility have made MSCs a major focus of medical research and clinical therapy. Common sources of MSCs include bone marrow, umbilical cord, placental tissue, adipose tissue, endometrium, dental pulp, peripheral blood, synovial membrane, and synovial fluid. According to the minimal criteria established by the International Society for Cellular Therapy (ISCT), MSCs must fulfill three conditions: (i) adhere to plastic under standard culture conditions; (ii) express the surface markers CD73, CD90, and CD105, while lacking expression of hematopoietic markers (CD34, CD45, CD14 or CD11b, CD79α or CD19, and HLA-DR); and (iii) demonstrate in vitro multipotent differentiation potential into osteoblasts, adipocytes, and chondrocytes under specific inductive conditions [23]. Furthermore, MSCs from different sources possess distinct biological characteristics and clinical applications due to their tissue of origin [24]. Bone marrow represents one of the most frequently used sources; its advantages include relative accessibility and extensive historical use in clinical applications [7, 25, 26]. Adipose-derived MSCs (AD-MSCs) generally exhibit higher proliferative activity and can be obtained in larger quantities, making them suitable for diverse therapeutic uses [27, 28]. Umbilical cord-derived MSCs (UC-MSCs) are often applied in treating premature ovarian insufficiency and neonatal injuries, benefiting from a non-invasive collection procedure and strong self-renewal capacity [8, 29, 30]. Placenta-derived MSCs, with their specific marker expression profiles, are commonly investigated for conditions like preeclampsia [31]. Dental pulp-derived MSCs show considerable potential in regenerative dentistry, while synovial-derived MSCs are frequently used for joint disease therapies. Although clinical applications sometimes overlap across different MSC sources, each source often offers unique advantages. For example, while both bone marrow-derived and adipose-derived MSCs can be used to treat osteoarthritis, research by Zhang et al. suggests that AD-MSCs may provide superior therapeutic stability [32]. MSCs possess robust differentiation capacity, enabling them to develop into various cell types, including osteocytes, chondrocytes, adipocytes, and neurons, under appropriate inductive conditions [33]. Beyond multilineage differentiation, MSCs exhibit considerable immunomodulatory properties (Fig. 1) [34]. Their low immunogenicity stems primarily from minimal expression of major histocompatibility complex (MHC) class I molecules and absence of MHC class II and co-stimulatory molecules such as CD80, CD86, and CD40. Consequently, MSCs cannot effectively activate lymphocytes, leading to T cell anergy [35]. The immunomodulatory effects of MSCs are mediated through three primary mechanisms: direct cell-to-cell contact, secretion of soluble factors, and metabolic regulation. via the context of cell contact-dependent regulation, MSCs from various tissue sources modulate the differentiation and function of T helper cell subsets. For instance, they suppress Th17 cell differentiation and promote regulatory T cell (Treg) development through secreted immunomodulatory factors such as TGF-β, IL-10, and PGE2 [9]. Additionally, studies demonstrate that bone marrow-derived MSCs (BM-MSCs) inhibit antigen-dependent B cell proliferation and plasma cell differentiation via PD-1/PD-L1 interactions [36]. Second, MSCs modulate immune responses through the secretion of soluble factors. Cytokines such as IL-6, IL-10, PGE2, and TGF-β suppress Th1 and Th17 differentiation while promoting Treg generation [10]. Furthermore, MSC-derived CCL2 inhibits plasma cell signaling and reduces immunoglobulin production [37]. In dendritic cells (DCs), MSC-secreted IL-6 and M-CSF restrict their differentiation [38]. Finally, metabolic regulation constitutes a critical component of MSC immunomodulation. MSCs express indoleamine-2,3-dioxygenase (IDO), which catalyzes the conversion of tryptophan to kynurenine, thereby inducing T cell apoptosis [11]. They also upregulate inducible nitric oxide synthase (iNOS), which impairs T cell activation, proliferation, and function through nitric oxide (NO)-mediated tryptophan metabolism [39]. Immunomodulatory mechanisms of MSCs MSCs regulate immune responses through three major mechanisms: metabolic regulation, cell-to-cell contact, and secretion of soluble factors. Metabolic regulation: MSCs express IDO, which depletes tryptophan and produces kynurenine, thereby inhibiting T-cell and NK-cell activation while promoting Treg development. iNOS–derived NO further suppresses T cells, NK cells, and dendritic cells. Cell-to-cell contact: Direct interactions between MSCs and immune cells deliver inhibitory or regulatory signals. Such contacts suppress T-cell, B-cell, NK-cell, and macrophage activation, while promoting the induction of regulatory phenotypes including Tregs, regulatory B cells, and M2 macrophages. Soluble factors: MSCs secrete a broad spectrum of immunomodulatory cytokines and chemokines—such as PGE2, TGF-β, IL-10, IL-6, CCL2, and M-CSF—which modulate immune-cell activity. These soluble mediators inhibit effector T cells, B cells, plasma cells, NK cells, and dendritic cells, while driving macrophage polarization toward the M2 phenotype and supporting regulatory immune subsets. Created with BioRender.com. MSCs and HSCT MSCs for HSC engraftment Hematopoietic reconstitution is a critical process in HSCT. Its failure is often associated with toxicities from pre-transplantation conditioning regimens, HLA incompatibility, and other factors [40]. Failed hematopoietic reconstitution can lead to severe clinical consequences, including an increased risk of infection, challenges in managing GVHD, disease transformation or recurrence, and reduced patient survival. Current clinical strategies for managing hematopoietic reconstitution failure include the use of potentiating agents such as erythropoietin (EPO), granulocyte colony-stimulating factor, thrombopoietin (TPO), CD34 + selected stem cell boosts, and secondary transplantation. However, these approaches are limited by variable efficacy and significant complications. Recent preclinical studies indicate that MSCs can significantly enhance HSC engraftment. In an autologous mouse transplantation model, AD-MSCs and HSC interaction markedly improved both short- and long-term hematopoietic reconstitution. This effect was particularly pronounced and dose-dependent in rodents exposed to moderate-dose radiation [41]. Furthermore, in a xenotransplantation mouse model, the co-transplantation of umbilical cord blood-derived MSCs with HSCs not only facilitated successful HSC engraftment but also significantly promoted the expansion of CD34 + cells [42]. Clinical trials have corroborated the safety and efficacy of MSCs in promoting HSC engraftment. in an open-label, multicenter trial involving 46 patients with hematologic malignancies, MSCs (at doses of 1.0–5.0 × 10⁶/kg) were co-infused with HSCs. The results showed that all patients tolerated the MSCs infusion well, with no infusion-related adverse events reported, and 91.3% of patients achieved rapid hematopoietic recovery [43]. Another study of 35 children with SAA demonstrated that all patients who underwent haploidentical HSCT co-transplanted with bone marrow-derived MSCs (BM-MSCs) successfully achieved hematopoietic reconstitution. The median time to engraftment was 14 days, which was significantly shorter than the 16-day benchmark reported in the existing literature, and no graft failure occurred [44]. In a prospective, open-label, randomized controlled trial, 22 patients with engraftment failure following autologous HSCT were randomized to receive either MSCs monotherapy or MSCs combined with cord blood. after one treatment cycle, seven patients in the MSC monotherapy group achieved complete remission (CR) or partial remission (PR), compared with nine patients in the MSC plus cord blood group. Moreover, the time to hematopoietic reconstitution was shorter in the combination therapy group [45]. The niche plays a crucial role in maintaining and regulating the bone marrow microenvironment for stem cells. Current research indicates that MSCs are an essential component of the HSC niche [46]. together, MSCs and HSCs establish a specialized hematopoietic microenvironment (Fig. 2). Studies have shown that nestin-expressing cells, which are MSCs, highly express genes related to HSC maintenance. Depleting nestin-positive cells in vivo significantly impairs HSC homing to the bone marrow, suggesting that MSCs facilitate HSC homing and engraftment [47]. Specifically, when MSCs and HSC are co-transplanted, MSCs enhance the homing of HSC to the bone marrow, thereby increasing the number of HSC in this compartment [48]. The mechanisms underlying this process primarily involve stromal cell-derived factor-1 (SDF-1) and the transcription factor HOXB4. MSCs secrete SDF-1, activating the SDF-1/CXCR4 axis to promote HSC homing. Concurrently, increased HOXB4 expression supports HSC proliferation and self-renewal [49]. Additionally, during co-transplantation, UC-MSCs upregulate the expression of vascular endothelial growth factor A (VEGF-A), osteopontin (OPN), and SDF-1α in the bone marrow via paracrine signaling. VEGF-A, a key angiogenic factor, promotes HSC survival by inhibiting apoptosis and supports HSC growth through paracrine effects. OPN, a major component of the bone marrow, helps maintain the reconstitution potential of HSCs. SDF-1α facilitates HSC homing via the SDF-1/CXCR4 axis. Through the upregulation of these key factors, MSCs promote HSC homing, proliferation, and engraftment [50]. Moreover, placenta-derived MSCs (P-MSCs) secrete matrix metalloproteinase-3 (MMP3), which may accelerate HSC homing by degrading the extracellular matrix in the bone marrow [51]. Beyond paracrine functions, MSCs contribute structurally to the hematopoietic niche by producing and remodeling extracellular matrix (ECM) components, such as collagen, fibronectin, and laminin, that provide physical support and biochemical cues for hematopoietic stem and progenitor cells [52]. MSCs also regulate HSC maintenance and differentiation through direct cell–cell interactions mediated by key signaling pathways, including N-cadherin-dependent adhesion, Jagged-1/Notch, SCF/c-Kit, and VCAM-1/ITGA-4 interactions, among others [46]. However, MSCs do not persist long-term in the bone marrow, and their prolonged presence is not required for their beneficial effects [53]. Instead, MSCs exert most of their regulatory functions through the secretion of bioactive molecules, underscoring the importance of paracrine mechanisms over direct engraftment or differentiation. These contact-dependent mechanisms work in concert with soluble factors to maintain hematopoietic homeostasis within the bone marrow microenvironment [54]. In addition, MSCs exhibit a distinct homing capacity toward the bone marrow and toward inflamed or injured tissues, guided by chemokine gradients. This allows them to localize precisely to sites of immune activation or tissue damage, where they exert reparative and immunomodulatory functions [55]. Proposed mechanism of MSCs therapy for protecting HSC MSCs support HSC homeostasis through both direct interactions and paracrine signaling. First, cell–cell contact pathways, including N-cadherins, Jagged-1/Notch, SCF/c-Kit, and VCAM-1/ITGA-4, facilitate adhesion and deliver essential survival and quiescence signals to HSCs. Second, MSCs secrete multiple trophic factors—such as SDF-1/CXCL12, SCF, VEGF, and OPN—which enhance HSC maintenance, promote retention within the marrow microenvironment, and protect HSCs from apoptosis. MSCs also contribute to ECM remodeling and interact with endothelial cells to help preserve vascular niche integrity. Furthermore, MSC activity inhibits HSC apoptosis, likely through combined effects of chemokine signaling and direct niche support. Created with BioRender.com. MSCs against PGF PGF is a common and serious complication following allo-HSCT and poses a significant threat to patient survival. The pathogenesis of PGF primarily involves damage to the bone marrow microenvironment and an imbalance in the composition of T-cell subsets within the marrow [56, 57]. Current therapeutic strategies for PGF include the administration of growth factors [58], eltrombopag [59], CD34+-selected stem cell boosts [60, 61], and secondary transplantation [62]. However, these treatments are often limited by unpredictable efficacy and various complications. In recent years, MSCs have been recognized as pivotal components of the bone marrow hematopoietic microenvironment, where they help coordinate the self-renewal and differentiation of HSC. Consequently, MSCs have emerged as promising candidates for preventing and treating PGF, with preliminary studies supporting their therapeutic potential. For example, in a prospective study, patients received an infusion of third-party donor bone marrow-derived MSCs at a dose of 1 × 10⁶/kg. Results showed that 17 patients responded to MSCs therapy, with no short-term toxicities observed, indicating a significant therapeutic benefit for PGF following allo-HSCT [63]. In a multicenter phase II clinical trial involving 44 patients with SAA who underwent haploidentical HSCT combined with MSCs infusion, co-transplantation of MSCs significantly reduced the incidence of graft failure after a median follow-up of 12 months [64]. Another study of 14 pediatric patients receiving related HLA-haploidentical transplants with donor-derived MSC co-transplantation (mean dose 1.6 × 10⁶ MSCs/kg) reported successful engraftment in all MSC-treated patients and no infusion-related adverse events. By contrast, among 47 historical controls, 7 patients experienced primary or secondary graft failure [65]. Research indicates that successful HSC engraftment depends on functional interactions between HSC and the bone marrow microenvironment [56]. In contrast, PGF, a state of hematopoietic dysfunction, is characterized by damage to the bone marrow microenvironment and impaired HSC function. MSCs are a critical cellular component of the bone marrow niche. Through their multilineage differentiation capacity, MSCs help regulate the bone marrow microenvironment and may thereby contribute to the improvement of PGF. A key mechanism involves the balancing of osteogenic and adipogenic differentiation by MSCs, which in turn modulates HSC function and activity [66, 67]. Adipocytes have been shown to exert an inhibitory effect on hematopoiesis within the marrow. Adipose tissue secretes factors such as TNF-α and adiponectin, which suppress the activity of hematopoietic progenitor cells and thereby negatively regulate hematopoiesis [68, 69]. In contrast, osteoblasts produce supportive hematopoietic growth factors, partly through pathways involving parathyroid hormone (PTH) or PTH-related protein (PTHrP) [70]. Therefore, maintaining a proper balance between osteogenesis and adipogenesis is essential for normal hematopoietic function. Multiple factors can shift the differentiation bias of MSCs, including aging, stress responses, radiation therapy [67], and chemotherapy [71]. These influences can lead to a skewed lineage commitment, which significantly compromises bone marrow hematopoietic function. Consequently, promoting the osteogenic differentiation of MSCs represents a potential strategy for enhancing the hematopoietic capacity of the bone marrow [66]. MSCs and GVHD GVHD is a common complication following HSCT. It is classified by severity into grades I–IV, with severe cases posing life-threatening risks. GVHD is also categorized chronologically as acute (aGVHD) or chronic (cGVHD [72]). aGVHD primarily results from the activation of donor T lymphocytes that recognize host antigens, leading to cytotoxic effects and the secretion of inflammatory cytokines that cause tissue damage [73]. The first-line treatment for aGVHD is glucocorticoids. Second-line options include calcineurin inhibitors (e.g., cyclosporine), mTOR inhibitors (e.g., sirolimus), antimetabolites (e.g., methotrexate), and monoclonal antibodies (e.g., basiliximab) [74]. However, these conventional therapies are often limited by glucocorticoid resistance and significant side effects. Given their potent immunomodulatory and anti-inflammatory properties, MSCs have been increasingly used for the prevention and treatment of GVHD. Clinical trials investigating MSCs for GVHD are summarized in Table 1. Table 1Clinical trials of MSCs in HSCTNo.Clinical trial IDStudy titlePhaseStudy typeDieaseSource of MSCDose1NCT01765634Mesenchymal stem cells for treatment of refractory acute graft-versus-host diseaseIIOpen LabelaGVHDBM1 × 10^6 /kg2NCT01765660Mesenchymal stem cells for treatment of refractory chronic graft-versus-host diseaseIIOpen LabelcGVHDBM1 × 10^6 /kg3NCT02824653Allogenic bone marrow mesenchymal stem cells infusion in patients with steroid-refractory GVHDI/IIOpen LabelSR-aGVHDBM/4NCT01941394Mesenchymal stem cells infusion for aGVHD prophylaxis transplantationIIOpen Labelallo-HSCT//5NCT01956903Treatment of refractory acute graft-versus-host disease by sequential infusion of allogenic mesenchymal stem cellI/IIOpen LabelaGVHD/0.7 × 10^6 /kg6NCT04692376MSC for treatment of cGVHD after Allo-HSCTIIOpen LabelcGVHD/1 × 10^6 /kg7NCT00827398Treatment of steroid resistant GVHD by infusion MSCI/IIOpen LabelSR-GVHD//8NCT00366145Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease (GVHD)IIIRandomized, Double, Blind, Placebo-ControlledSR-aGVHD/2 × 10^6 /kg9NCT05333029Extracorporeal photopheresis and mesenchymal stem cell infusion for GVHDIIOpen LabelaGVHD/2 × 10^6 /kg10NCT01589549Mesenchymal stromal cells for acute graft versus host diseaseIIOpen LabelaGVHD//11NCT00749164Allogeneic mesenchymal stem cell for graft-versus-host disease treatmentI/IIOpen LabelSR-aGVHDUC1–2 × 10^6 /kg12NCT02291770Treatment of chronic graft-versus-host disease with mesenchymal stromal cellsIIIOpen LabelcGVHD/2 × 10^6 /kg13NCT02379442Early treatment of acute graft versus host disease with bone marrow-derived mesenchymal stem cells and corticosteroidsI/IIOpen LabelaGVHD/2 × 10^6 /kg14NCT00972660Safety and efficacy study of allogenic mesenchymal stem cells to treat extensive chronic graft versus host diseaseIIrandomized, non blindedcGVHD/2 × 10^6 /kg15NCT06149832Treatment of oral chronic graft-versus-host disease with human umbilical cord mesenchymal stem cell dressingⅣOpen LabelcGVHD/1 × 10^6 /kg16NCT01526850Efficacy and safety study of allogenic mesenchymal stem cells for patients with chronic graft versus host diseaseII/IIIRandomized, ControlledcGVHD/1-2 × 10^7 /kg17NCT02241018MSCs combined with CD25 monoclonal antibody and calcineurin inhibitors for treatment of steroid-resistant aGVHDII/IIIOpen LabelaGVHDBM1 × 10^6 /kg18NCT03847844UCMSCs as front-line approach of treatment for patients with aGVHDI/IIINTERVENTIONALaGVHDUC5 × 10^6 /kg19NCT01754454Safety and efficacy of UC-MSC in patients with acute severe graft-versus-host diseaseI/IIOpen LabelaGVHDUC1 × 10^6 /kg20NCT05152160Umbilical cord mesenchymal stem cells in the treatment of moderate/severe chronic graft-versus-host diseaseI/IIOpen LabelcGVHDUC/21NCT03158896Evaluation of umbilical cord-derived wharton’s jelly stem cells for the treatment of acute graft versus host diseaseIOpen LabelaGVHDUC2-10 × 10^6 /kg22NCT02770430Mesenchymal stem cells as first treatment line for resistant acute graft versus host diseaseIIOpen LabelSR-GVHDBM2 × 10^6 /kg23NCT02687646Clinical trial with MSC for graft versus host disease treatmentI/IIOpen LabelGVHDAD0.7-1 × 10^6 /kg24NCT01764100Mesenchymal stromal cells (MSCs) for the treatment of graft versus host disease (GVHD)IOpen LabelSR-GVHD/1 ± 0.5 × 10^6 /kg25NCT00603330Mesenchymal stem cell infusion as treatment for steroid-resistant acute graft versus host disease (GVHD) or poor graft functionIIOpen LabelSR-aGVHD/4 × 10^6 /kg26NCT00136903Safety and efficacy study of adult human mesenchymal stem cells to treat acute graft versus host disease (GVHD)IIOpen LabelaGVHD/2 × 10^6 /kg27NCT00447460Treatment of refractory (acute or chronic) graft-versus-host disease by the infusion of expanded in-vitro allogenic mesenchymal stem cellI/IIOpen LabelGVHD/1-2 × 10^6 /kg28NCT00504803Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host diseaseIIOpen LabelHSCTUC/29NCT01318330Safety study of homeo-GH (bone marrow derived clonal mesenchymal stem cell) to treat acute/chronic graft versus host disease (GVHD)IOpen LabelGVHDBM1 × 10^6 /kg30NCT01549665Umbilical cord blood-derived mesenchymal stem cells for the treatment of steroid-refractory acute or chronic graft-versus-host-diseaseI/IIOpen LabelSR-GVHDUC1-3 × 10^6 /kg31NCT04629833Treatment of steroid-refractory acute graft-versus-host disease with mesenchymal stromal cells versus best available therapyIIIRandomized, Open-labelSR-aGVHD/1-2 × 10^6 /kg32NCT04738981Efficacy and safety of UC-MSCs for the treatment of steroid-resistant aGVHD following allo-HSCTIIIRandomized, Open-labelSR-aGVHDUC1 × 10^6 /kg33NCT06321198A trial to evaluate the safety and preliminary efficacy of imesenchymal stromal cells (iMSC) in subjects with SR-aGVHD/Open LabelSR-aGVHD//34NCT00361049Donor mesenchymal stem cell infusion in treating patients with acute or chronic graft-versus-host disease after undergoing a donor stem cell transplantIOpen LabelGVHD//35NCT03631589MSC for severe aGVHDII/IIIOpen LabelaGVHD//36NCT05531266Umbilical cord mesenchymal stem cells as first-line treatment for patients with acute graft versus host disease/Randomized, ControlledaGVHDUC1 × 10^6 /kg37NCT05443464Mesenchymal stem cells (MSCs) for steroid refractory acute GVHD (SR-aGVHD)IOpen LabelSR-aGVHD/2 × 10^6 /kg38NCT02336230A prospective study of remestemcel-L, ex-vivo cultured adult human mesenchymal stromal cells, for the treatment of pediatric participants who have failed to respond to steroid treatment for acute graft-versus-host disease (aGVHD)IIIOpen LabelaGVHD/2 × 10^6 /kg Clinical trials of MSCs in HSCT Multiple clinical trials have demonstrated the efficacy and safety of MSCs in both preventing and treating aGVHD. A retrospective analysis by Bacigalupo et al. reported that infusion of bone marrow- or umbilical cord-derived MSCs at the time of transplantation significantly reduced the incidence of aGVHD and was associated with a one-year survival rate of 80% in patients [75]. In a randomized study on aGVHD prophylaxis involving 77 patients with hematologic malignancies, participants were assigned to either a standard prophylaxis regimen or a group receiving additional MSCs co-prophylaxis (mean dose 1.2 × 10⁶/kg). The results showed that MSCs infusion reduced the incidence of aGVHD from 20.5% to 10.2% and significantly improved overall survival [76]. Furthermore, clinical trials have established the utility of MSCs, both as monotherapy and in combination, for treating steroid-refractory aGVHD (SR-aGVHD). Several studies confirm that MSCs alone are effective in managing SR-aGVHD [77–79]. Improved outcomes have also been observed when MSCs are combined with second-line agents [80] or with the monoclonal antibody basiliximab [81]. Induced pluripotent stem cell (iPSC)-derived MSCs represent another promising therapeutic option for SR-aGVHD. In a phase I, multicenter, open-label, dose-escalation study, 16 subjects with SR-aGVHD received a single infusion of iPSC-derived MSCs at either 1 × 10⁶/kg (cohort A) or 2 × 10⁶/kg (cohort B). The treatment was well-tolerated, with no significant differences in safety profiles between the two dose levels. iPSC-derived MSCs offer a more sustainable and scalable cell source, leveraging the unlimited expansion capacity of iPSCs to overcome the manufacturing limitations of conventional MSCs isolates [82]. Beyond their application in aGVHD, MSCs have demonstrated significant potential in the prevention and treatment of cGVHD. cGVHD is characterized by abnormal T- and B-cell activation, tissue fibrosis, regulatory T-cell dysfunction, and microbiota dysregulation, which collectively lead to diverse clinical manifestations affecting multiple organs such as the skin, oral cavity, eyes, and liver [83]. Accumulating clinical evidence supports the utility of MSCs in both preventing and treating cGVHD. Two meta-analyses have concluded that MSC administration significantly reduces the incidence of cGVHD [84, 85]. In a multicenter, randomized, double-blind, Phase II controlled trial including 124 patients with hematologic malignancies, participants were assigned (1:1) to receive either umbilical cord-derived MSCs (3 × 10⁷ cells per 100 mL monthly) or placebo for cGVHD prevention. The MSCs group received a mean of 3.7 infusions (range 2–4). Results demonstrated a significantly lower cumulative incidence of cGVHD in the MSC group compared to the control group (P = 0.021). Immunological analysis revealed an increased number of Tregs and an altered Th1/Th2 ratio following MSC infusion, suggesting that MSCs mediate their protective effect through immunomodulation [86]. Regarding cGVHD treatment, a prospective Phase I/II clinical study enrolled 10 patients with steroid-refractory cGVHD who received bone marrow-derived MSCs at a dose of 1 × 10⁶/kg. All 10 patients achieved a partial response by 8 weeks post-infusion, with no serious adverse events reported [87]. In a separate study involving 22 patients with refractory dry eye symptoms secondary to cGVHD, 12 patients showed symptomatic improvement after MSCs therapy [88]. Additionally, a clinical report on four patients with scleroderma-related cGVHD noted symptomatic improvement in all cases following MSC infusion [89]. Relevant Clinical trials investigating MSCs for GVHD are summarized in Table 1. MSCs primarily alleviate GVHD through multifaceted immunomodulatory mechanisms (Fig. 3). A key mechanism involves the suppression of CD3⁺CD4⁺ and CD3⁺CD8⁺ T-cell populations while promoting the expansion and activation of regulatory T cells (Tregs [90]), thereby modulating the Th1/Th2 balance. MSCs inhibit Th1 differentiation and foster immune tolerance, ultimately attenuating effector T-cell-mediated immune attack [15]. Additionally, MSCs secrete macrophage polarization factors, including IL-4, IL-10, and M-CSF, that drive macrophages toward an M2 phenotype. These M2 macrophages migrate to injury sites, where they exert anti-inflammatory effects [91]. Most intravenously infused MSCs become trapped in the pulmonary microvasculature and rapidly undergo apoptosis. host macrophages then phagocytose these apoptotic MSCs, further polarizing toward an M2-like phenotype with elevated secretion of IL-10 and TGF-β [92]. This process amplifies the immunomodulatory and tissue-repair functions of MSCs, suggesting that their therapeutic benefits may stem largely from the host’s clearance of apoptotic cells rather than long-term engraftment. MSCs also interact closely with monocytic myeloid-derived suppressor cells (M-MDSCs), which exhibit potent immunoregulatory properties in inflammatory and transplant settings [93]. Studies have shown that MSCs can promote the proliferation and activation of M-MDSCs by secreting soluble factors such as PGE2, IL-6, and HGF [94]. Subsequently, M-MDSCs suppress the proliferation and cytokine production of effector T cells through Arg-1- and iNOS-dependent pathways. This bidirectional interaction establishes a highly immunosuppressive microenvironment and may play a pivotal role in the induction of immune tolerance mediated by MSCs. MSCs also inhibit the activation and antigen-presenting function of DCs, reducing T cell recognition of recipient transplant antigens and thereby lowering the risk of GVHD [95]. MSCs can also alter the migration patterns of T cells and DCs, redirecting T cells toward secondary lymphoid organs and ameliorating clinical manifestations of acute GVHD [96]. In contrast to acute GVHD, cGVHD involves not only T cells but also aberrant B-cell activation. Following HSCT, the reconstitution of donor-derived B cells is often accompanied by disrupted B-cell homeostasis, leading to autoantibody production and cGVHD initiation [97, 98]. As key components of the hematopoietic microenvironment, MSCs help regulate B lymphopoiesis via pathways involving parathyroid hormone (PTH), Wnt signaling, and estrogen [99]. Peng et al. reported that MSCs reduce B-cell activating factor (BAFF) levels while inducing BAFF receptor expression, thereby modulating B-cell subset distribution, expanding CD27⁺ memory B-cell numbers, and alleviating cGVHD symptoms [100]. MSCs also regulate the proliferation and function of regulatory B cells (Bregs) through direct cell contact and soluble factors, promoting IL-10 secretion and enhancing their anti-inflammatory activity [16]. MSCs secrete anti-fibrotic mediators such as IL-10 and HGF, which suppress the activation of fibroblasts and myofibroblasts. In addition, MSCs can release factors including HGF and TNF-α–stimulated gene/protein 6 (TSG-6) to inhibit the phosphorylation of Smad2/3, thereby attenuating fibrogenic signaling at its source. Immunomodulatory effects of MSCs on the pathogenesis of GVHD In aGVHD (left), MSCs attenuate the acute, T cell–driven inflammatory response by suppressing the activation and proliferation of effector CD4⁺ and CD8⁺ T cells, as well as Th1 and Th17 subsets. Meanwhile, MSCs promote the expansion of Tregs. Through the secretion of immunoregulatory mediators—including IDO, PGE2, and NO—MSCs inhibit DC activation and impair antigen presentation. MSCs also enhance the generation of M-MDSCs and polarize macrophages toward an anti-inflammatory M2 phenotype, collectively dampening the cytokine-driven inflammatory cascade characteristic of aGVHD. In cGVHD (right), MSCs primarily target dysregulated B-cell immunity. MSCs inhibit B-cell activation and suppress the production of BAFF, thereby reducing aberrant B-cell survival signals. Concurrently, MSCs promote the expansion of regulatory Bregs, which further restore immune homeostasis through the secretion of IL-10. In addition to immune modulation, MSCs mitigate tissue fibrosis—a hallmark of cGVHD—by downregulating fibroblast activation and extracellular matrix deposition via HGF, IL-10, and inhibition of the TGF-β/Smad signaling pathway. Created with BioRender.com. MSCs and other transplant complications The clinical application of MSCs for managing complications beyond GVHD in HSCT is emerging, though research in this area remains limited. One promising indication is hemorrhagic cystitis (HC). Retrospective studies suggest that MSCs can effectively treat BK virus-associated HC in children. In one series, 13 pediatric patients received weekly MSCs infusions (1 × 10⁶/kg), with a median of two infusions per patient. All children responded to treatment, with eight achieving complete resolution and five showing symptomatic improvement, corresponding to a 100% overall response rate [17]. Similarly, a report on four pediatric patients with grade 3–4 HC described complete remission in all cases following MSCs therapy [101]. In adults, A separate retrospective analysis reported treatment response in five of six patients with HC, yielding an 83.3% response rate [102]. Thrombotic microangiopathy (TMA) represents another potential target. In a representative case, a 9-year-old girl with severe aplastic anemia developed transplant-associated TMA (TA-TMA) after HSCT. She received a single MSC infusion (2 × 10⁶/kg) without infusion-related adverse events. Within 24 h, her lysostaphin levels decreased markedly, and defibrotide was discontinued by day 12. Although multiple biological parameters normalized within two weeks, TA-TMA recurred after 10 weeks, and the patient ultimately died from multiorgan failure 190 days post-HSCT [103]. Despite this outcome, the case provides preliminary insight into a potential therapeutic role for MSCs in TMA. Furthermore, MSCs may help repair tissue injury following HSCT. In a study by Ringdén et al., 10 patients received MSCs at a median dose of 1.0 × 10⁶/kg. The cohort included seven individuals with grade 2–5 HC, two with mediastinal emphysema, and one with colonic perforation and peritonitis. After MSCs infusion, five patients with severe HC experienced symptom resolution, and both patients with mediastinal emphysema recovered fully [104]. Although current evidence is limited, these preliminary findings indicate the potential utility of MSCs in managing diverse HSCT-related complications. Key aspects such as efficacy, safety, and optimal dosing require further validation in future clinical trials. Patients with hematologic malignancies are at high risk of infection due to disease- or treatment-related immunodeficiency, as well as impairments in leukocyte number or function. These infections frequently progress to sepsis or systemic inflammatory response syndrome, representing a major cause of morbidity and mortality following HSCT or chemotherapy [105]. In this setting, MSC-based therapeutic strategies may offer dual benefits: modulating excessive immune activation and exerting direct or indirect antibacterial effects. studies have demonstrated that MSCs secrete antimicrobial peptides, including LL-37, lipocalin-2, and β-defensins, which effectively inhibit bacterial growth and enhance pathogen clearance [106]. Furthermore, MSCs enhance the phagocytic activity of macrophages and neutrophils via Toll-like receptor signaling pathways, thereby improving bacterial clearance and attenuating systemic inflammatory responses [107]. These combined mechanisms suggest that MSCs may help mitigate infection-related complications in immunocompromised patients with hematologic diseases, extending their potential clinical utility beyond immunomodulation and tissue repair. MSCs and hematologic malignancies MSCs exert dual effects in hematologic malignancies, demonstrating both pro-tumorigenic and anti-tumorigenic properties (Fig. 4) [108]. On the pro-tumorigenic side, MSCs can inhibit tumor cell apoptosis in vitro. For example, Manabe et al. reported that MSCs prolonged the survival of B-lineage acute lymphoblastic leukemia (ALL) cells. In 15 of 18 B-lineage ALL cases, the number of viable cells decreased by more than 50% after 72 h in culture alone. However, when co-cultured with allogeneic bone marrow stromal feeder layers, MSCs significantly reduced apoptosis in 10 of those cases, thereby extending leukemic cell survival [19]. Similarly, Panayiotidis et al. observed that 7 of 10 chronic lymphocytic leukemia (CLL) samples remained viable for 30 days when cultured with MSCs, an effect that was abolished when physical contact was prevented using culture filters, indicating the importance of direct MSC–tumor cell adhesion [109]. Garrido et al. also demonstrated that direct contact with HS-5 human stromal cells significantly suppressed apoptosis in acute myeloid leukemia (AML) cells from 30 patients compared to transwell culture [110]. Additionally, MSCs secrete pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and angiopoietin-1, which promote tumor vascularization and growth [111, 112]. MSCs may also enhance tumor cell stemness and foster a permissive microenvironment for disease progression [113, 114]. Conversely, MSCs can also exert anti-tumor effects by inhibiting tumor cell proliferation. Song et al. showed that MSCs suppressed the growth of mouse lymphoma and leukemia cells in vitro, and in vivo MSCs injection reduced lymphoma incidence [115]. Tian et al. reported that MSCs co-cultured with leukemic cell lines inhibited tumor proliferation, primarily through cell cycle arrest at the G0/G1 phase [18]. Imilarly, Yuan et al. found that human UC-MSCs suppressed the proliferation of Jurkat leukemia cells in vitro [116]. Beyond cell cycle blockade, MSCs inhibit angiogenesis by suppressing endothelial cell proliferation, potentially via the VE-Cadherin/β-catenin signaling pathway [117]. Studies have also shown that MSCs can induce endothelial cell apoptosis in vitro and exhibit anti-lymphoma activity in vivo [118]. The dual role of MSCs in tumorigenesis The pro-tumorigenic effects (left) include providing vascular support to promote tumor angiogenesis and enhancing cancer stemness to facilitate tumor initiation and progression. The anti-tumorigenic effects (right) involve inhibiting vascularization, inducing endothelial cell apoptosis, and promoting tumor cell cycle arrest, collectively leading to tumor suppression. The net effect depends on the tumor microenvironment, MSCs source, and interactions with resident cells. Several clinical strategies are being developed to counteract the pro-tumorigenic potential of MSCs and improve therapeutic outcomes. One approach involves selecting MSCs sources with inherently lower pro-tumor activity. Studies indicate that UC-MSCs exhibit stronger immunomodulatory and anti-tumor properties than BM-MSCs. UC-MSCs secrete microRNAs and proteins that target signaling pathways such as Wnt/β-catenin, PI3K/Akt, and TGF-β/Smad, thereby suppressing tumor growth and metastasis [119]. Thus, prioritizing UC-MSCs over BM-MSCs may help reduce pro-tumor risks [120]. Enhancing the intrinsic anti-tumor activity of MSCs represents another strategy. MSCs secrete Dickkopf-1 (DKK1), a Wnt pathway inhibitor that downregulates c-Myc and cyclin D2 while upregulating P21CIP1 and P27KIP1, ultimately suppressing acute myeloid leukemia (AML) cell proliferation [121]. Accordingly, DKK1 agonists may amplify the anti-tumor effects of MSCs [122]. Wang et al. developed a cryopreservation method that abolishes MSCs proliferation and pro-tumorigenicity while retaining tumor-homing capacity, creating a safe and effective vehicle for targeted drug delivery, as validated in vitro [123]. Single-cell analyses reveal that pro- and anti-tumor MSCs subpopulations coexist within the AML niche. Using single-cell omics to identify specific markers of these subpopulations could enable the selective expansion of anti-tumor MSCs, helping to resolve their functional duality [124]. Genetic engineering offers a further avenue for optimization. CRISPR/Cas9 technology can be applied to tailor MSCs to patient-specific genetic profiles, for instance by modulating osteogenic differentiation via Notch signaling to shift MSCs from a pro- to an anti-tumor phenotype [125]. Finally, MSC-derived extracellular vesicles (MSC-EVs) represent a promising cell-free alternative. by encapsulating anticancer drugs, MSC-EVs can deliver therapeutic cargo while avoiding the risks associated with whole-cell therapies [126]. In summary, strategies focusing on source selection, functional enhancement, subpopulation mapping, genetic editing, and cell-free derivatives hold significant potential for overcoming the pro-tumor effects of MSCs in the treatment of hematologic malignancies. Genetically modified MSCs can serve as sustainable sources of high-concentration therapeutic molecules, enabling precise drug delivery to tumor microenvironments for localized, targeted treatment. For instance, MSCs engineered to express TNF-related Apoptosis-Inducing Ligand (TRAIL) demonstrate significant anti-myeloma activity in vitro, suggesting a promising strategy for multiple myeloma (MM) therapy [127, 128]. TRAIL is a member of the TNF superfamily that selectively induces apoptosis in cancer cells while sparing normal cells [129]. It exerts this effect by engaging death receptors DR4 and DR5 [130]. Since MSCs themselves do not express DR4 or DR5, they serve as ideal vehicles for TRAIL delivery, enhancing tumor-specific targeting [131]. Additionally, MSCs can be designed as bioreactors for producing and delivering tetravalent bispecific tandem antibodies. One study reported engineered MSCs secreting bioactive Tandab (CD3/BCMA), which contains dual binding sites for both CD3 and B-cell maturation antigen (BCMA). These modified MSCs exhibit enhanced chemotaxis toward MM cells, enabling selective elimination of BCMA‑positive primary and precursor cells, reducing tumor burden, and exerting therapeutic effects in MM models [132]. In B-cell lymphoma, MSCs have been engineered to secrete CD3/CD19 bispecific antibodies. In animal models, these cells migrate specifically to tumor sites, bind both CD3⁺ and CD19⁺ cells, and induce selective lysis of CD19⁺ populations. When combined with the IDO pathway inhibitor D-1MT, particularly in MSCs co‑expressing dogurmodin, the proportion of lysed target cells increases significantly, enhancing antitumor efficacy in vivo [133]. MSCs and other non-malignant hematologic diseases AA is a hematologic disorder characterized by bone marrow failure to produce blood cells, leading to a severe reduction in peripheral blood cell counts. Studies have shown that BM-MSCs from AA patients exhibit significant impairments in their immunoregulatory and hematopoietic support functions. These dysfunctional MSCs promote the overproduction of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) by CD4 + T cells, thereby disrupting normal hematopoiesis. Furthermore, their compromised capacity to expand regulatory T cell populations creates an immune imbalance, which aggravates immune-mediated damage to the hematopoietic process. Additionally, MSCs from AA patients demonstrate a predisposition for adipogenic over osteogenic differentiation. This shift promotes adipogenesis and alters the bone marrow microenvironment, ultimately worsening disease progression [134]. However, some studies have reported that MSCs from AA patients can exhibit normal phenotypes and differentiation potential, along with largely preserved immunomodulatory and hematopoietic support functions [135]. These discrepancies may originate from several factors. First, variations in patient diagnostic criteria, disease severity, and prior treatment histories across different studies can significantly affect the phenotype and function of MSCs. Second, methodological heterogeneity, including differences in tissue sources, cell passage numbers, and in vitro functional assays, may also lead to inconsistent findings. Third, the bone marrow microenvironment in AA patients is characterized by immune-mediated inflammation, oxidative stress, and stromal damage, which can secondarily impair MSCs function to varying extents in different individuals. From a therapeutic standpoint, these observations carry important implications. Although autologous MSCs circumvent immune rejection, their functionality may be compromised by the underlying disease-related stromal injury, which can limit their therapeutic potential. In contrast, allogeneic MSCs from healthy donors can theoretically offer more robust hematopoietic support and immunomodulatory effects. However, their application carries potential risks, including immunogenicity and allo-sensitization. Therefore, future research should systematically compare the efficacy of autologous versus allogeneic MSCs in standardized AA models to identify the optimal treatment strategy. MSCs demonstrate therapeutic potential for AA by improving the bone marrow microenvironment and promoting hematopoietic recovery through multiple mechanisms, including immunomodulation, pro-angiogenic activity, anti-inflammatory effects, and direct support of hematopoietic stem cells. In a phase II multicenter trial involving 74 AA patients, a weekly intravenous infusion of BM-MSCs at a dose of 1–2 × 10⁶ cells/kg for four weeks resulted in an overall response rate of 28.4% (95% CI: 19%–40%), with 6.8% of patients achieving complete remission. Transient headache and fever occurred in seven patients, and no serious adverse events were reported, indicating a favorable safety profile [136]. Another clinical study of 18 AA patients receiving related-donor MSCs found that six patients achieved either complete or partial remission. Only two cases of mild, self-limiting fever were reported, with no other significant adverse events observed [137]. However, despite the consistent safety profile of MSCs therapy, its efficacy in achieving early remission and sustained hematologic improvement remains limited. In a trial of nine AA patients receiving two to five weekly infusions of BM-MSCs, only two exhibited a partial hematologic response after six months, with no evidence of MSCs engraftment detected in the bone marrow [138]. Similarly, an open-label, prospective Phase IV pediatric trial administered three weekly infusions of UC-MSCs (1 × 10⁶ cells/kg), starting 14 days after anti-thymocyte globulin (ATG) therapy. Among the nine subjects, only one achieved partial remission [139]. Several factors may contribute to this variable treatment response. Donor-related characteristics represent one key factor; BM-MSCs from younger donors contain higher proportions of certain functional subpopulations, while those from female donors exhibit a stronger capacity to suppress T-cell proliferation [140]. The patient’s specific immune status and microenvironmental conditions also modulate MSCs behavior. For instance, activation of Toll-like receptors (TLRs) polarizes MSCs into distinct functional states: TLR3 agonists enhance immunosuppressive mediator expression and inhibit T-cell activation, whereas TLR4 agonists promote pro-inflammatory cytokine secretion and counteract MSC-mediated immunosuppression [141]. Finally, the administration route and cell dosage significantly impact outcomes. After intravenous infusion, most MSCs are trapped in the pulmonary capillaries and cleared by monocytes within 24 h, leading to low delivery efficiency to the bone marrow [142]. Consistent with this, meta-analyses identify cell dose as a critical determinant of efficacy, underscoring the need to optimize dosing regimens in clinical practice [143]. ITP is an autoimmune disorder characterized by a markedly reduced platelet count and an elevated risk of bleeding. MSCs from ITP patients exhibit functional impairments, including diminished proliferative capacity and a reduced ability to inhibit T-cell proliferation. These abnormalities may be linked to the upregulation of caspase-9 and downregulation of p16 [144]. Furthermore, activation of the NF-κB/Smad pathway leads to a marked decrease in tumor necrosis factor α-inducible protein 3 (TNFAIP3) expression, which further compromises MSCs function. This MSC dysfunction not only impairs their intrinsic immunoregulatory roles but also hinders megakaryocyte production and platelet formation, thereby exacerbating ITP pathogenesis [145]. Consequently, restoring normal MSCs function has emerged as a potential therapeutic strategy for ITP. Pharmacologic interventions offer a means to resuscitate MSCs function and alleviate ITP. For instance, thalidomide has been shown to restore the ability of MSCs to regulate dendritic cells, potentially through the downregulation of caspase-8 and caspase-10 and the upregulation of oct3/4 and TGF-β1 [146]. Beyond pharmacological intervention, the infusion of healthy MSCs has also demonstrated efficacy in ITP. In a long-term follow-up study, four patients with chronic refractory ITP were treated with UC-MSCs. One patient achieved sustained remission after a single infusion, while the three patients who experienced relapse subsequently attained sustained remission following a second infusion [147]. In a prospective phase I clinical trial, 18 patients with ITP received escalating doses of UC-MSCs, resulting in an overall response rate of 44.4% (8/18), with 22.2% of patients achieving complete remission [148]. These outcomes further support the potential of MSC-based therapy for ITP. Proposed mechanisms underlying this therapeutic effect include the reversal of megakaryocyte dysfunction, promotion of platelet production, and reduction of early megakaryocyte apoptosis [149]. In summary, MSCs represent a promising therapeutic strategy for ITP, acting both through the correction of intrinsic functional defects and via the infusion of healthy MSCs to enhance platelet production and restore immune homeostasis. Future clinical studies are warranted to validate the efficacy of MSCs in ITP and to elucidate their precise mechanisms of action. Although most clinical studies report favorable short-term tolerability of MSC-based therapies, growing preclinical and clinical evidence indicates that intravenously administered MSCs may possess procoagulant activity. This activity is primarily attributed to variable expression of tissue factor (TF/CD142) and phosphatidylserine on the cell surface [150, 151] and appears more pronounced at higher cell doses or with specific tissue sources, such as adipose- or perinatal-derived MSCs. Several case reports and series have documented infusion-related thrombotic adverse events [152], prompting recommendations for hemocompatibility testing prior to clinical MSCs administration. For patients with thrombocytopenia, such as those with ITP or post-transplant cytopenia, these coagulation-related properties are of direct clinical relevance. On one hand, BM-MSCs have been shown to increase platelet counts in animal models of ITP [153], and clinical observations have reported platelet responses following MSCs infusion, suggesting potential therapeutic benefits through immune regulation and megakaryopoiesis support. On the other hand, the procoagulant potential of certain MSC preparations could increase microthrombosis risk in patients with severely compromised hemostasis or underlying prothrombotic conditions, and may interact unpredictably with concurrent antithrombotic or platelet-promoting therapies. The limitations of MSCs clinical translation Although numerous preclinical studies have demonstrated the therapeutic potential of MSCs in hematologic and immune-related disorders, most of these promising findings have not been successfully translated into clinical therapies. Several factors may account for this limited translatability. First, the inherent heterogeneity of MSCs products represents a major obstacle. MSCs derived from different tissue sources, such as bone marrow, umbilical cord, and adipose tissue, as well as from donors of varying age, sex, and health conditions, exhibit distinct proliferative capacities, secretory profiles, and immunomodulatory functions, leading to considerable variability in therapeutic efficacy [154]. Second, the lack of standardized definitions and manufacturing criteria for MSCs products complicates comprehensive quality control and precise potency assessment. As highlighted by Jai et al., unlike small-molecule drugs, MSCs are living cell products whose manufacturing, expansion, storage, and transport are subject to significant procedural variations. The absence of universally accepted potency assays—such as those quantifying immunosuppressive activity or VEGF secretion, further contributes to batch-to-batch inconsistencies in therapeutic outcomes [155]. Third, animal models used in preclinical research often fail to fully recapitulate the complexity of human diseases. These models typically involve young, genetically homogeneous animals that lack the comorbidities commonly present in human patients, limiting the predictive value of preclinical findings for clinical efficacy [155]. Fourth, MSCs generally exhibit low homing efficiency, limited retention in target tissues, and poor long-term survival in vivo, all of which significantly impair their therapeutic efficacy. Following intravenous infusion, a substantial proportion of MSCs become trapped in the lungs; although some redistribution occurs within 24–48 h, the number of cells ultimately reaching the target tissue remains low [156]. In addition to these challenges, disease heterogeneity, uncertainties regarding long-term safety, and an incomplete understanding of the underlying biological mechanisms further hinder the clinical translation of MSC-based therapies. Dose and routes of MSCs administration Currently, no universally accepted optimal dosage exists for MSCs therapy, with typical clinical doses ranging from 1 to 10 × 10⁶ cells/kg [157]. For GVHD, intravenous doses of 0.5–3 × 10⁶ cells/kg per infusion are most commonly used in clinical trials, with 1 × 10⁶ cells/kg serving as the most frequent empirical reference. Repeated administration, such as weekly infusions, is often employed to sustain immunomodulatory effects [158]. Regarding administration routes, MSCs can be delivered intravenously, intraosseously (intramedullary), locally, or via intra-arterial injection. intravenous infusion remains the predominant method due to its convenience, suitability for repeated dosing, and ease of clinical monitoring, despite its limitation in homing efficiency caused by pulmonary entrapment [142]. To improve site-specific delivery, various targeted strategies are under investigation, including intraosseous or intra-arterial infusion, organ-specific administration, incorporation into biomaterial scaffolds to enhance local retention, and the use of magnetic or ligand-guided targeting systems. Each method involves a balance among practicality, invasiveness, and regulatory complexity. Therefore, future studies should prioritize indication-specific optimization of MSCs delivery, supported by rigorous pharmacokinetic and pharmacodynamic analyses, to define the most effective administration strategies [159]. MSC-EVs Characteristics, advantages and disadvantages of MSC-EVs Extracellular vesicles (EVs) are heterogeneous membrane-bound structures released by cells and are broadly classified into three subtypes: exosomes (30–150 nm in diameter), which originate from endosomal multivesicular bodies; microvesicles (100–1000 nm), which are shed directly from the plasma membrane; and apoptotic bodies (up to 2 μm), which are released during programmed cell death [160–162]. These vesicles carry diverse bioactive cargo, including proteins, lipids, and nucleic acids such as mRNA and miRNA, and act as key mediators of intercellular communication. MSC-EVs can transfer functional components to recipient cells without direct cell–cell contact, thereby regulating a variety of biological processes [54, 163]. Compared to intact MSCs, MSC-EVs offer several clinical advantages. They exhibit greater physicochemical stability and are less susceptible to microenvironmental changes. Their surface lacks immunogenic markers such as MHC molecules, resulting in low immunogenicity and an improved safety profile. their nanoscale size enables traversal of biological barriers, including the blood–brain barrier, improving access to hard-to-reach tissues. Furthermore, their lipid bilayer membrane protects encapsulated bioactive molecules from degradation, enhancing delivery efficiency [164]. Functionally, MSC-EVs retain central features of parental MSCs, including immunomodulatory, tissue-reparative, regenerative, and anti-inflammatory activities. From a regulatory perspective, MSC-EVs are generally classified as biological products rather than advanced therapy medicinal products (ATMPs), which simplifies their clinical translation, manufacturing, and quality control relative to live-cell therapies [165, 166]. MSC-EVs also hold diagnostic potential. their stable molecular cargo, proteins, lipids, and nucleic acids, reflects the physiological or pathological state of originating cells. Studies have shown that MSC-EV-derived microRNAs and surface proteins can serve as biomarkers for immune activation, tissue injury, or progression of hematologic diseases [167, 168]. This utility not only aids diagnosis but may also help monitor treatment response in regenerative and hematologic contexts. The broad clinical applications of MSC-EVs are summarized in Table 2. Table 2Clinical trial of MSC-EVsNo.NCT numberStudy titlePhaseStudy typeDiseaseSource of MSCDose1NCT06853522hucMSCs exosomes for the treatment of active ulcerative colitisIRandomized, paralleledUlcerative ColitisUC/2NCT04213248Effect of UMSCs derived exosomes on dry eye in patients with cGVHDI/IIOpen LabelDry EyeUC10ug/drop3NCT05787288a clinical study on safety and effectiveness of mesenchymal stem cell exosomes for the treatment of COVID-19.IRandomized, paralleledCOVID-19 PneumoniaUC5 × 109 particles4NCT06697080Umbilical cord-derived mesenchymal stem cell exosomes on hair growth in patients with androgenetic alopeciaNARandomized, paralleled, triple blindedAndrogenic AlopeciaUC/5NCT04544215A clinical study of mesenchymal progenitor cell exosomes nebulizer for the treatment of pulmonary infectionI/IIRandomized, paralleledDrug-resistantAD8.0/16.0*108 nano vesicles/3 ml6NCT05871463Effect of mesenchymal stem cells-derived exosomes in decompensated liver cirrhosisIIOpen LabelDecompensated Liver CirrhosisUC40 mg7NCT06391307The role of mesenchymal stem cell and exosome in treating pilonidal sinus disease in childrenNAOpen LabelPilonidal Sinus//8NCT03437759MSC-exos promote healing of MHsIRandomized, paralleledMacular Holes//9NCT04276987A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumoniaIOpen LabelCoronavirusAD2.0*10E8 nano vesicles/3 ml10NCT05808400Safety and efficacy of umbilical cord mesenchymal stem cell exosomes in treating chronic cough after COVID-19INon-Randomized, paralleledLong COVID-19 SyndromeAD5*10^9 particles11NCT06568653Human placenta mesenchymal stem cells derived exosomes injection for treatment of complex anal fistulaIIOpen LabelFistula PerianalPlacenta/12NCT05499156Safety of injection of placental mesenchymal stem cell derived exosomes for treatment of resistant perianal fistula in crohn’s patientsI/IIRandomized, paralleled, double blindedPerianal Fistula in Patients With Crohn’s DiseasePlacenta/13NCT04356300Exosome of mesenchymal stem cells for multiple organ dysfuntion syndrome after surgical repaire of acute type a aortic dissectionNARandomized, paralleled, single blindedMultiple Organ Failure/150 mg14NCT05738629Safety and efficacy of pluripotent stem cell-derived mesenchymal stem cell exosome (PSC-MSC-Exo) eye drops treatment for dry eye diseases post refractive surgery and associated with blepharospasmI/IIOpen LabelDry Eye DiseasePluripotent Stem Cell0.125 ml/single eye/one time15NCT06764004The effect of human umbilical cord mesenchymal stem cells and exosomes on the healing of postoperative pain and periapical lesions in the treatment of apical periodontitis: randomized controlled clinical studyI/IIRandomized, paralleled, single blindedApical PeriodontitisUC/16NCT06245746UCMSC-exo for chemotherapy-induced myelosuppression in acute myeloid leukemiaIOpen LabelAcute Myeloid LeukemiaUC/17NCT05813379Mesenchymal stem cells derived exosomes in skin rejuvenationI/IIOpen LabelAnti Aging//18NCT05669144Co-transplantation of mesenchymal stem cell derived exosomes and autologous mitochondria for patients candidate for CABG surgeryI/IIRandomized, paralleledMyocardial InfarctionUC100 µg?19NCT06677931Umbilical cord mesenchymal stem cell-derived exosomes in the treatment of melasmaNARandomized, paralleled, quadraple blindedMelasmaUC/20NCT04313647A tolerance clinical study on aerosol inhalation of mesenchymal stem cells exosomes in healthy volunteersINon-Randomized, paralleledHealthy//21NCT05523011Safety and tolerability study of MSC exosome ointmentIOpen LabelPsoriasis/100 ?g22NCT04850469Study of MSC-Exo on the therapy for intensively ill childrenOpen LabelSepsis|Critical Illness//23NCT05152368Safety of cultured allogeneic adult umbilical cord stem cells exosomes for trigeminal neuralgiaIOpen LabelPeripheral Neuropathy/Trigeminal NeuralgiaUC/24NCT06812637Efficacy and safety of Wharton’s jelly-derived mesenchymal stem cell exosomes in the treatment of diabetic foot ulcers: a double-blinded randomized controlled clinical trialIRandomized, paralleled, triple blindedDiabetic Foot Ulcer//25NCT05152394Safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for Parkinson’s diseaseIOpen LabelParkinson DiseaseUC/26NCT05158101Safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosome intranasal instillations for strokeIOpen LabelStrokeUC/27NCT04602104A clinical study of mesenchymal stem cell exosomes nebulizer for the treatment of ARDSI/IIRandomized, paralleled, double blindedAcute Respiratory Distress Syndrome/2.0/8.0/16.0*10^8 particles28NCT05216562Efficacy and safety of EXOSOME-MSC therapy to reduce hyper-inflammation in moderate COVID-19 patientsI/IIRandomized, paralleled, triple blindedSARS-CoV2 Infection//29NCT04798716The use of exosomes for the treatment of acute respiratory distress syndrome or novel coronavirus pneumonia caused by COVID-19I/IIRandomized, double blindedCovid19|Novel Coronavirus Pneumonia|Acute Respiratory Distress Syndrome/2.0/4.0/8.0 * 10^930NCT06919380Nebulized MSC-Exos for anti-MDA5 + RP-ILD: safety and efficacy trialIOpen LabelAnti-MDA5 Positive Dermatomyositis-Associated RP-ILD/Rapidly Progressive Interstitial Lung Disease//31NCT05387278Safety and effectiveness of placental derived exosomes and umbilical cord mesenchymal stem cells in moderate to severe acute respiratory distress syndrome (ARDS) associated with the novel corona virus infection (COVID-19)IRandomized, paralleled, quadraple blindedCOVID-19 Acute Respiratory Distress Syndrome/Respiratory Distress SyndromePlacenta/32NCT04388982The safety and the efficacy evaluation of allogenic adipose MSC-Exos in patients with Alzheimer’s diseaseI/IIOpen LabelAlzheimer DiseaseAD5/10/20µg Clinical trial of MSC-EVs Recent studies indicate that the therapeutic effects of MSCs are mediated, at least in part, through apoptosis-dependent mechanisms and vesicles released by apoptotic MSCs. Evidence suggests that apoptotic MSCs are essential for inducing immunosuppressive responses in vivo, and that cryopreservation and thawing do not diminish their anti-inflammatory function [169]. Antonio et al. reported that intravenously infused MSCs undergo apoptosis in vivo, and recipient mononuclear phagocytes recognize and engulf these apoptotic cells via efferocytosis, a key step in triggering subsequent immunosuppression [92]. A series of preclinical studies have isolated extracellular vesicles from apoptotic MSCs (ApoEVs) and apoptotic bodies, demonstrating that these vesicles can polarize macrophages toward an M2-like phenotype, suppress T-cell responses, and promote tissue repair in various injury models [170, 171]. Several direct or mechanistic comparative studies further indicate that, for certain immunological outcomes, ApoEVs or apoptotic MSCs can replicate, and in some cases exceed, the immunomodulatory effects of viable MSCs or extracellular vesicles from living cultures [6]. However, their therapeutic efficacy remains dependent on factors such as ApoEV subtype, preparation method, and dosage [172]. Together, these findings suggest that future translational studies should systematically compare the efficacy of viable MSCs, conventional small extracellular vesicles (e.g., exosomes), and specific ApoEV subpopulations in standardized preclinical models to identify the optimal therapeutic paradigm and dosing strategy. MSC-EVs and HSCT Similar to MSCs, MSC-EVs have been shown to support hematopoietic reconstitution and engraftment following transplantation. Preciado et al. demonstrated that supplementing CD34⁺ hematopoietic stem cell cultures with MSC-EVs significantly enhanced their clonogenic potential and bone marrow homing capacity, indicating a direct supportive role in early hematopoietic recovery [173]. Similarly, De Luca et al. reported that microRNAs and piRNAs encapsulated in bone marrow MSC-EVs promote cell survival and inhibit premature differentiation of cord blood-derived HSC, offering new mechanistic insights into their pro-engraftment function [174]. Furthermore, Schoefinius et al. found that MSC-EVs alone could rescue lethally irradiated mice and sustain long-term survival without additional HSC support, highlighting their intrinsic hematopoietic protective properties [175]. To date, no large-scale clinical trials have specifically evaluated the efficacy of MSC-EVs for PGF, and current evidence remains largely derived from mechanistic and early exploratory studies. MSC-EVs also exhibit considerable anti-inflammatory potential and hold promise for preventing and treating GVHD. They can suppress the proliferation of effector CD4⁺ and CD8⁺ T cells [176] and modulate immune responses by promoting a shift from Th1 to Th2 polarization while reducing Th17 cell levels [177]. Additionally, MSC-EVs inhibit DC maturation, recruit monocytes and macrophages to inflammatory sites, and promote macrophage polarization toward the M2 phenotype [178], mechanisms that closely mirror those of their parent MSCs. In a mouse allogeneic-HSCT model, umbilical cord-derived MSC-EVs effectively ameliorated symptoms and histopathological changes of aGVHD and significantly reduced aGVHD-related mortality [179]. Su et al. further demonstrated that MSC-EVs can serve as a drug delivery platform: when loaded with arsenic trioxide (ATO), they repolarized M1 macrophages to the M2 phenotype via mTOR inhibition, thereby improving aGVHD while preserving the graft-versus-lymphoma (GVL) effect [21]. In a mouse model of allo-HSCT, infusion of MSC-EVs alleviated symptoms of aGVHD, significantly improved histopathological findings, and notably reduced recipient mortality [179]. Beyond aGVHD, the immunoregulatory properties of MSC-EVs also extend to cGVHD. Studies have demonstrated that MSC-EVs administration can prolong survival in cGVHD mouse models, alleviate clinical symptoms, and ameliorate fibrosis in affected tissues such as the skin, lungs, and liver. In a clinical setting, Kordelas et al. reported the first successful use of MSC-derived exosomes in a pediatric patient with severe, therapy-refractory GVHD who had failed to respond to standard immunosuppressive treatment. Following repeated intravenous infusions of MSC-derived exosomes, the patient showed a marked reduction in pro-inflammatory cytokine levels and significant clinical improvement, with no observable adverse effects [163]. Although preclinical studies indicate that MSC-EVs exhibit functions similar to those of MSCs in the context of HSCT, current research remains largely confined to laboratory and animal models. large-scale, multicenter clinical trial data are still lacking to definitively establish the safety and efficacy of MSC-EVs [22]. Engineered MSC-EVs Engineered MSC-EVs represent a class of specialized nanoscale delivery systems designed for precise therapeutic applications. These vesicles are produced through the in vitro modification of MSC-EVs using biotechnological approaches that enhance their drug-loading capacity, targeting specificity, stability, and therapeutic efficacy [180–182]. two primary strategies are employed for engineering MSC-EVs. The first is progenitor cell engineering, in which MSCs are genetically modified to overexpress specific targeting ligands or therapeutic proteins, leading to the secretion of EVs bearing these engineered traits [183–185]. The second approach involves post-isolation modification, where isolated EVs are functionalized via techniques such as electroporation or co-incubation to load drugs, nucleic acids, or targeting molecules into preformed vesicles [185, 186]. Engineered MSC-EVs overcome several limitations of conventional EVs by offering improved drug encapsulation efficiency, enhanced preservation of therapeutic cargo activity, and the ability for cell-specific targetin [187]. They also retain low immunogenicity and high biocompatibility, rendering them particularly suitable for clinical translation [188]. Owing to these advantages, engineered MSC-EVs are increasingly studied for hematologic malignancies. For example, Jin et al. genetically modified UC-MSCs to overexpress a Lamp2b–IL3 fusion protein. Since IL-3R is highly expressed on leukemia stem cells (LSCs), exosomes derived from these engineered MSCs exhibited enhanced bone marrow homing and specific targeting of LSCs. When loaded with miR-34c-5p, a key regulator of cellular senescence, these MSC-EVs promoted the elimination of LSCs in vivo. Importantly, the treatment showed no observable toxicity in the heart, liver, lungs, or kidneys, supporting its favorable safety profile [189]. In another study, Yang et al. employed UC-MSCs to deliver oncolytic reovirus. The resulting UC-MSC-EVs served as viral carriers, entering acute myeloid leukemia (AML) cells via clathrin-mediated endocytosis and macropinocytosis, thereby enhancing antitumor efficacy [190]. Although engineered MSC-EVs represent a promising platform for treating hematologic diseases, their applications remain in early stages. further clinical trials and translational studies are needed to fully realize their therapeutic potential. Despite the considerable therapeutic promise of MSC-EVs, several technical and translational challenges limit their clinical application. The most commonly used isolation method, differential ultracentrifugation, suffers from limitations such as low purity, difficult resuspension, and lengthy processing times. Alternative commercial isolation kits are available, but often lack transparent or precise descriptions of their separation principles [191]. These production challenges hinder the scalable, reproducible, and GMP-compliant manufacturing of MSC-EVs. Moreover, the inherent complexity of MSC-EVs products, which vary in cellular origin and mechanism of action, complicates the establishment of consistent Critical Quality Attributes (CQAs), creating another barrier to clinical translation [192]. Standardized protocols for the stable, long-term storage of MSC-EVs have also not been established, posing a further obstacle to their reliable clinical use [193]. Beyond manufacturing and storage, monitoring the distribution and pharmacokinetics of MSC-EVs following administration remains technically difficult. Although nanoparticle tracking analysis is available, it cannot reliably distinguish EVs from other extracellular nanoparticles and has not yet been standardized for large-scale clinical application [194]. Addressing These challenges through continued research and process optimization is essential to fully realize the clinical potential of MSC-EVs. Comparison between MSCs and MSC-EVs A growing body of preclinical evidence indicates that MSC-EVs retain much of the paracrine and immunomodulatory capacity of their parent MSCs, while circumventing risks inherent to live-cell therapies, including vascular occlusion and alloimmunization. MSC-EVs also present practical benefits in storage stability and manufacturing standardization [195]. Multiple preclinical studies report that MSC-EVs can produce therapeutic outcomes comparable to those of primary MSCs in models of neurological protection, lung injury, and kidney injury. however, these effects are highly influenced by the animal model employed, EV dosage, and the specific isolation and purification methods used [196, 197]. Notably, MSCs and MSC-EVs are not functionally interchangeable. In settings that demand sustained local microenvironmental interaction or direct cell–cell contact, such as in long-term hematopoietic niche reconstitution, viable MSCs may exhibit superior efficacy. In contrast, for therapies where paracrine signaling is the primary mechanism, where biological barriers must be traversed, or where cell-free formulations are advantageous for safety and regulatory reasons, MSC-EVs may hold a clear advantage. Thus, MSCs and MSC-EVs address complementary therapeutic niches, and their applications should be selected according to the specific demands of each clinical context. Conclusion MSCs and MSC-EVs hold significant promise for treating hematologic diseases. in HSCT, MSCs contribute to engraftment, aid in the prevention and management of GVHD, and mitigate post-transplant complications such as PGF and hemorrhagic cystitis. These benefits stem from their multipotent differentiation capacity, immunomodulatory functions, and ability to support hematopoiesis. MSCs have also shown efficacy in non-malignant hematologic disorders, including AA and ITP. in hematologic malignancies, however, MSCs exhibit a “double-edged sword” effect, demonstrating both pro-tumor and anti-tumor activities. Notably, they can be engineered as delivery vehicles for targeted therapeutic agents. Meanwhile, MSC-EVs offer a cell-free alternative with similar efficacy in preventing and treating HSCT-related complications, particularly GVHD, while avoiding risks associated with live-cell infusion. Despite this promise, several challenges impede clinical translation, including the need for standardized production protocols, functional heterogeneity among products, and uncertainties regarding long-term safety. Future progress will depend on optimizing cell sources, improving EV isolation techniques, and conducting large-scale clinical trials. Through such advances, MSCs and MSC-EVs are poised to become cornerstone strategies in the treatment of hematologic disorders, furthering the goals of precision and regenerative medicine. This review provides a novel integrative perspective by synthesizing recent advances in both MSCs and MSC-EVs therapies. By comparing cell-based and vesicle-based strategies and incorporating emerging insights into apoptotic MSC-derived vesicles and their mechanisms, we present a unified and updated framework not previously covered in earlier reviews. This synthesis helps clarify how EV-centered approaches are reshaping the therapeutic landscape of MSCs in hematology. MSCs mesenchymal stem cells, HSCT hematopoietic stem cell, aGVHD acute graft versus host diaease, cGVHD chronic graft versus hoet disease, SR-aGVHD steroid-refractory acute graft versus host disease, UC umbilical cord, AD adipose, BM bone marrow. Acknowledgements Figures in this manuscript were created with BioRender.com. Abbreviations Mesenchymal stem cells Graft-versus-host disease Acute graft-versus-host disease Chronic graft-versus-host disease Immune thrombocytopenia Severe aplastic anemia Extracellular vesicles derived from MSCs Hematopoietic stem cell transplantation Allogeneic hematopoietic stem cell transplantation Poor graft function Adipose-derived MSCs Umbilical cord-derived MSCs Tonsil-derived MSCs Regulatory T cells Monocytic myeloid-derived suppressor cells Dendritic cells Tryptophan-metabolizing enzyme indoleamine-2,3-dioxygenase Nitric oxide synthase Erythropoietin Thrombopoietin Complete remission Partial remission Bone marrow-derived MSCs Stromal cell-derived factor-1 Homeobox protein B4 Vascular endothelial growth factor Osteopontin Matrix metalloproteinase 3 Chemokine receptor type 4 Parathyroid hormone Parathyroid hormone-related protein Hormone-refractory acute GVHD Pluripotent stem cell B cell activating factor B regulatory cells Hemorrhagic cystitis Thrombotic microangiopathy Transplantation-associated thrombotic microangiopathy Acute myeloid leukemia TNF-related Apoptosis-Inducing Ligand Multiple myeloma Death receptors 4 B-cell maturation antigen Tumor necrosis factor-alpha Interferon-gamma Toll-like receptor Tumor necrosis factor α-inducible protein 3 Extracellular vesicles Extracellular vesicles derived from apoptotic MSCs Major histocompatibility complex Arsenic trioxide Graft-versus-lymphoma effect Leukemia stem cellsLSCs Author contributions MXD drafted the manuscript. XYZ and YCZ edited the manuscript. All the authors critically revised and provided final approval for the manuscript. Funding This work was supported by grants from the National High Technology Research and Development Program of China (2021YFA1101504), the Key Research and Development Program of Hubei Province (No. 2022BCA017). Data availability Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.